Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-325 in healthy volunteers
NCT07158437Phase 1Active, not recruiting
- Sponsor
- Shattuck Labs
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SL-325 in inflammatory bowel disease (IBD) (4 arms), sponsored by Shattuck Labs. Primary endpoint: Safety and Tolerability. Started Sep 2025; status: active, not recruiting.
02
Drugs
SL-325
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07158437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158437.